rethinkTHC Search
Menu
Study breakdown

CBD relieves nerve pain in mice partly through the opioid system

Animal StudyPreliminary evidence
The takeaway

CBD produced pain relief in mice with nerve injury, and this effect was partially reversed by blocking mu and delta opioid receptors in the paw, revealing a peripheral opioid mechanism.

People interested in how CBD works for pain relief, and researchers studying cannabinoid-opioid interactions.

CBD analgesia was reversed by blocking mu and delta opioid receptors but not kappa receptors

What the researchers found

CBD at 20 mg/kg produced significant antinociception in mice with sciatic nerve injury. Naloxone (a general opioid blocker) reversed this effect. Selective mu (CTOP) and delta (naltrindole) opioid receptor antagonists partially reversed CBD analgesia, but the kappa antagonist (norBNI) did not.

Why it matters

CBD is widely discussed as a pain treatment, but its mechanisms remain poorly understood. This study identifies a specific pathway: CBD appears to activate peripheral opioid receptors (mu and delta types) as part of how it reduces nerve pain, which could help optimize future pain therapies.

The numbers in context

CBD at 20 mg/kg produced antinociception. Bestatin (400 microg/paw), an aminopeptidase inhibitor, potentiated the effect of a subtherapeutic CBD dose (2 mg/kg). Naloxone (50 microg/paw) reversed CBD analgesia. CTOP (mu antagonist) and naltrindole (delta antagonist) partially reversed the effect; norBNI (kappa antagonist) did not.

How the study worked

Male Swiss mice underwent sciatic nerve constriction injury to model neuropathic pain. Nociceptive threshold was measured using a mechanical paw pressure test. CBD was given systemically at 20 mg/kg, and various opioid receptor antagonists were injected locally into the paw to test which receptor subtypes were involved.

What this study cannot tell us

This is a mouse study using a surgical nerve injury model. Only male mice were tested. The doses and routes of administration may not translate directly to humans. The study does not clarify whether CBD acts directly on opioid receptors or triggers endogenous opioid release.

How to read the evidence

Single animal study in male mice using a nerve injury model, with pharmacological evidence for a specific mechanism.

When this study was published

Published in 2025.

The bigger picture

The finding that CBD engages the peripheral opioid system without being an opioid itself is significant. If CBD can activate endogenous opioid pathways without the addiction and respiratory depression risks of direct opioids, it could represent a safer approach to pain management. The potentiation by bestatin suggests CBD may work by enhancing the body's own opioid peptides.

Questions still open

  • Does CBD trigger release of endogenous opioid peptides, or does it interact with opioid receptors through another mechanism? Would this peripheral opioid pathway be relevant in human neuropathic pain? Could CBD enhance the effects of low-dose opioid therapy?

Common questions

Does this mean CBD is an opioid?
No. CBD is not an opioid, but this study found it appears to activate the body's own opioid pathways as part of its pain-relieving mechanism. This is different from drugs like morphine that directly bind opioid receptors.
Which opioid receptors were involved?
Mu and delta opioid receptors in the peripheral nervous system (tested in the paw) were involved. Kappa opioid receptors were not part of CBD's analgesic mechanism in this model.

Read the original research

Cannabidiol engages the peripheral endogenous opioid system to produce analgesia in neuropathic mice.

Neuroscience letters, 868, 138393

Citation

de Almeida, Douglas Lamounier; Pinto Barra, Walace Cássio; Mendes Ferreira, Renata Cristina; Fonseca, Flávia Cristina; Dias Machado, Daniel Portela; Aguiar, Danielle Diniz; Guimaraes, Francisco Silveira; Gama Duarte, Igor Dimitri; Lima Romero, Thiago Roberto. (2025). Cannabidiol engages the peripheral endogenous opioid system to produce analgesia in neuropathic mice.. Neuroscience letters, 868, 138393. https://doi.org/10.1016/j.neulet.2025.138393

Explore the wider topic